



March 24, 2014

## **Xencor to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference**

MONROVIA, Calif., March 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel & Conference Center in New York, NY.

A live audio webcast of the presentation will be available on the "Events and Presentations" section in the Investors section of the company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentation will be posted on the Xencor website approximately one hour after the event and will be available for 30 days following the presentation.

### **About Xencor, Inc.**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology. Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.

For more information, please visit [www.xencor.com](http://www.xencor.com).

SOURCE Xencor, Inc.

News Provided by Acquire Media